Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain.


Journal

Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264

Informations de publication

Date de publication:
05 2020
Historique:
received: 17 04 2019
accepted: 28 11 2019
pubmed: 21 12 2019
medline: 22 4 2021
entrez: 21 12 2019
Statut: ppublish

Résumé

The aim of the presented study was to examine the potential antinociceptive, antiedematous (anti-inflammatory), and antiallodynic activities of two 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives (DSZ 1 and DSZ 3) in various experimental models of pain. For this purpose, the hot plate test, the capsaicin test, the formalin test, the carrageenan model, and oxaliplatin-induced allodynia tests were performed. In the hot plate test, only DSZ 1 in the highest dose (20 mg/kg) was active but its effects appear to be due to sedatation rather than antinociceptiveness. In capsaicin-induced neurogenic pain model, both compounds displayed a significant antinociceptive activity. In the formalin test, DSZ 1 and DSZ 3 (5-20 mg/kg) revealed antinociceptive activity in both phases but it was more pronounced in the second phase of the test. In this test, pretreatment with caffeine, DPCPX reversed the antinociceptive effect of DSZ 3. On the other hand, pretreatment with L-NAME diminished the antinociceptive effect of DSZ 1. Pretreatment with naloxone did not affect antinociceptive activity of both compounds. Similar to ketoprofen, DSZ 1 and DSZ 3 showed antiedematous (antiinflammatory) and antihyperalgesic activity, and similar to lidocaine local anesthetic activity. Furthermore, both compounds (5 and 10 mg/kg) reduced tactile allodynia in acute and chronic phases of neuropathic pain. In the in vitro studies, DSZ 1 and DSZ 3 reduced the COX-2 level in LPS-activated RAW 264.7 cells, which suggests their anti-inflammatory activity. In conclusion, both DSZ 1 and DSZ 3 displayed broad spectrum of activity in several pain models, including neurogenic, tonic, inflammatory, and chemotherapy-induced peripheral neuropathic pain.

Identifiants

pubmed: 31858155
doi: 10.1007/s00210-019-01783-3
pii: 10.1007/s00210-019-01783-3
doi:

Substances chimiques

Analgesics 0
Anti-Inflammatory Agents 0
Pyridones 0
Receptor, Adenosine A1 0
Nitric Oxide 31C4KY9ESH
Ptgs2 protein, mouse EC 1.14.99.-
Cyclooxygenase 2 EC 1.14.99.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

813-827

Références

Brain Res Rev. 2006 Aug;51(2):240-64
pubmed: 16388853
Nitric Oxide. 2011 Oct 30;25(3):243-54
pubmed: 21723953
Exp Brain Res. 2009 Jun;196(1):5-11
pubmed: 19294370
Eur J Pharmacol. 2005 Apr 18;513(1-2):81-91
pubmed: 15878712
Eur J Pharmacol. 2012 Jan 15;674(2-3):248-54
pubmed: 22085758
J Neurosci Methods. 1985 Jun;14(1):69-76
pubmed: 4033190
Neurosci Lett. 2008 Aug 1;440(2):181-4
pubmed: 18562097
Eur J Pharmacol. 2009 Mar 1;605(1-3):95-102
pubmed: 19168051
Neurosci Lett. 2010 Apr 12;473(3):178-81
pubmed: 20176083
Pharmacol Biochem Behav. 2015 Aug;135:13-9
pubmed: 25989045
Farmaco. 2005 Jan;60(1):53-9
pubmed: 15652370
Pharmazie. 2001 Feb;56(2):133-8
pubmed: 11234340
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13525-30
pubmed: 17686976
Biomed Pharmacother. 2019 Mar;111:882-890
pubmed: 30841467
Eur J Pain. 2014 Aug;18(7):939-48
pubmed: 24395183
Toxicol Lett. 2016 Sep 6;258:93-100
pubmed: 27329536
Molecules. 2016 Jun 28;21(7):
pubmed: 27367653
Eur J Pharmacol. 1991 Aug 16;201(1):121-2
pubmed: 1665419
J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
pubmed: 18152921
Eur J Pharmacol. 1995 Apr 13;277(1):21-8
pubmed: 7635169
Pharmacol Res. 2005 Mar;51(3):197-203
pubmed: 15661568
Br J Anaesth. 2017 Oct 1;119(4):737-749
pubmed: 29121279
Neuropharmacology. 2013 Feb;65:206-12
pubmed: 23098993
Acta Pol Pharm. 2006 Jul-Aug;63(4):245-54
pubmed: 17203859
Eur J Med Chem. 2018 Oct 5;158:517-533
pubmed: 30245393
Acta Pol Pharm. 2017 Mar;74(2):435-443
pubmed: 29624249
Pharmacol Biochem Behav. 2014 Jul;122:173-81
pubmed: 24726707
Arch Int Pharmacodyn Ther. 1957 Sep 1;111(4):409-19
pubmed: 13471093
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
pubmed: 14001233
Int J Biochem Cell Biol. 2006;38(10):1654-61
pubmed: 16713323
Farmaco. 2002 Nov;57(11):897-908
pubmed: 12484538
J Pharmacol Exp Ther. 1953 Mar;107(3):385-93
pubmed: 13035677
Eur J Pharmacol. 2001 Aug 24;426(1-2):39-44
pubmed: 11525769
J Zhejiang Univ Sci B. 2015 Mar;16(3):167-78
pubmed: 25743118
Pharmacol Rep. 2016 Dec;68(6):1285-1292
pubmed: 27689756
J Basic Clin Physiol Pharmacol. 1994 Apr-Jun;5(2):125-31
pubmed: 8736044
Free Radic Biol Med. 2011 Sep 1;51(5):951-66
pubmed: 21277369
Neuroscience. 2016 Dec 3;338:1-18
pubmed: 26500181
Nitric Oxide. 2015 May 1;47:17-24
pubmed: 25754796

Auteurs

Anna Dziubina (A)

Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland. anna.dziubina@uj.edu.pl.

Dominika Szkatuła (D)

Department of Chemistry of Drugs, Faculty of Pharmacy with Division of Laboratory Diagnostics, Wroclaw Medical University, Borowska 211, 50-556, Wrocław, Poland.

Joanna Gdula-Argasińska (J)

Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland.

Magdalena Kotańska (M)

Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland.

Barbara Filipek (B)

Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH